Drug combo shows promise for tough cancers
NCT ID NCT02856425
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nintedanib when given with pembrolizumab. The study aimed to see if this combination could be better tolerated and more effective than either drug alone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Léon Bérard
Lyon, 69008, France
-
Gustave Roussy
Villejuif, Val De Marne, 94805, France
-
Hôpital Bichat
Paris, 75018, France
-
IUCT--O
Toulouse, 31059, France
-
Institut Bergonié
Bordeaux, 33000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can AI-Guided home training boost recovery from gastric cancer surgery?
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Could a vaccine help fight Hard-to-Treat cancers?